Published • loading... • Updated
CRISPR’s next act: the companies editing the epigenome to treat disease
Summary by Bioethics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CRISPR’s next act: the companies editing the epigenome to treat disease
(Nature) – A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder. The idea is to remove or add epigenetic markers — essentially chemical groups that sit on DNA (and the proteins that it is wound around). Depending on which chemical group is present or absent, genes can be activated or switched off. Some existing medications influence epigene…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
